Sermorelin vs Ipamorelin

Two growth-hormone-releasing peptides that work through different receptors. No ranking.

Sermorelin and ipamorelin both prompt the pituitary to release growth hormone, through different receptors. Sermorelin is a GHRH analog; ipamorelin acts on the ghrelin (growth hormone secretagogue) receptor. No FDA-approved drug contains ipamorelin, and FDA lists safety concerns about compounding it. Compounded sermorelin is not FDA-approved either. A licensed provider decides what fits.

Compounded sermorelin is not FDA-approved; sermorelin was approved as Geref in 1997 and discontinued in 2008.

See if sermorelin fits me

Opens the Sermorelin application on OpenLoop, in English. Our care team can help in English or Spanish.

Sermorelin vs ipamorelin at a glance

Facts as published by FDA and in the cited studies; sources linked below, read 2026-11-02. No ranking is implied.
	Sermorelin	Ipamorelin
What it is	A 29-amino-acid GHRH analog that acts on the pituitary’s GHRH receptor	A synthetic five-amino-acid peptide that acts on the ghrelin / growth hormone secretagogue receptor, a different pathway from GHRH
FDA status	Compounded sermorelin is not FDA-approved. Sermorelin acetate was approved as Geref in 1997 for children with growth hormone deficiency and is no longer marketed.	No FDA-approved product. FDA placed ipamorelin acetate in category 2 (may present significant safety risks) of its 503B compounding interim policy on September 29, 2023.
Route	Injection under the skin (subcutaneous)	Given into a vein (intravenously) in the published human trial
Published dosing convention	Geref in children: 30 µg/kg once daily at bedtime. Adult research studies used 0.5 to 2 mg once or twice daily.	No approved dose. A phase 2 trial after bowel surgery used 0.03 mg/kg intravenously twice daily for up to 7 days.
Cost category	Compounded prescription. At REMEVi: $229 every 4 weeks (28 days), month-to-month	No approved product to price; REMEVi does not offer ipamorelin
Usually discussed for	Adults asking a licensed provider about the growth-hormone axis; historically, children with growth hormone deficiency	Studied in hospital for slow bowel function after surgery (postoperative ileus); discussed online in wellness settings

Doses are shown as published, for orientation, not as a dosing guide. A licensed provider sets any dose; never self-dose.

See if sermorelin fits me

Opens the Sermorelin application on OpenLoop, in English. Our care team can help in English or Spanish.

What is the difference between sermorelin and ipamorelin?

They reach the same gland by different routes. Sermorelin copies the active part of growth-hormone-releasing hormone and acts on its receptor. Ipamorelin is a small synthetic peptide that acts on the ghrelin receptor instead. Their regulatory status also differs: sermorelin was once an approved drug (Geref), while no FDA-approved product has ever contained ipamorelin.

Is ipamorelin FDA-approved?

No. No FDA-approved drug contains ipamorelin. FDA lists ipamorelin acetate in category 2 of its 503B compounding interim policy, citing immunogenicity concerns and a published report of serious adverse events, including death, when it was given intravenously. It is also not one of the six peptides in HHS’s October 2026 interim compounding policy.

FDA adds that it lacks enough safety information to know whether ipamorelin would cause harm when injected by other routes. The six peptides covered by HHS’s interim enforcement-discretion policy for 503A compounding (Federal Register, October 30, 2026) are BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c.

The 2026 peptide compounding policy, explained · Peptides at REMEVi

What the human evidence on ipamorelin shows

The early ipamorelin research was in rat pituitary cells, anesthetized rats and pigs, where it released growth hormone without raising the stress hormones ACTH or cortisol. That is animal and laboratory evidence. The main published human trial gave it intravenously to 114 adults after bowel surgery; time to tolerating a solid meal did not differ significantly from placebo.

Can sermorelin and ipamorelin be taken together?

A PubMed search found no published human trial of sermorelin and ipamorelin given together, and this page does not recommend combining them. Mechanisms alone do not show that a combination is safe. REMEVi prescribes sermorelin as a single-ingredient medication, and any decision about other medicines belongs to a licensed provider who knows your history.

More comparisons

Tesamorelin, the third peptide in this group, is a GHRH analog with its own FDA-approved label. Our older guide covers all three at once.

Sermorelin vs tesamorelin · Sermorelin vs ipamorelin vs tesamorelin compared · Sermorelin cost

Sources

Raun et al., Eur J Endocrinol 1998 — Ipamorelin, the first selective growth hormone secretagogue (read November 2, 2026)
Beck et al., Int J Colorectal Dis 2014 — Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients (read November 2, 2026)
FDA — Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (read November 2, 2026)
FDA — Drugs@FDA database (searched for ipamorelin: no product found) (read November 2, 2026)
HHS — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, Federal Register, October 30, 2026 (read November 2, 2026)
FDA — Orphan Drug Designations and Approvals: sermorelin acetate (Geref) (read November 2, 2026)
Prakash & Goa, BioDrugs 1999 — Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency (read November 2, 2026)
Corpas et al., J Clin Endocrinol Metab 1992 — Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men (read November 2, 2026)
Vittone et al., Metabolism 1997 — Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men (read November 2, 2026)

Medically reviewed by Linda West-Conforti, RN · CA RN #389453 · November 2, 2026